Folotyn: Newly Approved Hope for Rare Lymphoma

Those with relapsed and refractory peripheral T-cell lymphoma  -- a rare cancer -- now have the first treatment ever available for their disease. Folotyn (pralatrexate) was approved for this use just a few days ago by the FDA. This OK was based on the PROPEL trial, which showed early and newfound response in patients.  Of course, Folotyn is not without its side effects. Learn more by reading the FDA's news release on the approval.